This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy

This study has been withdrawn prior to enrollment.
(Patients were not interested in enrolling)
Information provided by (Responsible Party):
kalish hadas, Rabin Medical Center Identifier:
First received: May 11, 2011
Last updated: April 25, 2017
Last verified: April 2017

The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy.

Indices for follow-up will include:

  • Clinical activity score
  • Anti-TSH receptor antibody levels
  • Thickening of extraocular muscles per ultrasound
  • Quality of life score for Graves Orbitopathy patients

Condition Intervention Phase
Graves Ophthalmopathy Drug: Azithromycin Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy

Resource links provided by NLM:

Further study details as provided by kalish hadas, Rabin Medical Center:

Primary Outcome Measures:
  • Change in clinical activity score between baseline and after three months [ Time Frame: Three months ]

    Change in the clinical activity score between baseline and after 3 months

    (Clinical Activity Score is a validated index of Graves Ophthalmopathy that assigns one point to the presence of: 1.spontaneous retrobulbar pain, 2. pain on up/downgaze, 3. redness of eyelids, 4. redness of conjunctiva, 5. swelling of eyelids, 6. inflammation of caruncle/plica, 7. chemosis). The maximal clinical activity score is thus 7.

Secondary Outcome Measures:
  • Measurement of extraocular muscle thickening [ Time Frame: 3 months ]
    Ultrasonic measurement of extraocular muscle thickening

  • ANTI TSH Receptor antibody levels [ Time Frame: 0, 3 and 6 months ]
    Serum measurements of ANTI TSH Receptor antibody levels

Enrollment: 0
Study Start Date: May 2011
Study Completion Date: December 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azithromycin PO three times weekly
Tablets Azithromycin 500 mg PO three times weekly for three months
Drug: Azithromycin
Tab. Azithromycin 500 mg PO three times weekly for 3 months
Other Name: AZITRO

Detailed Description:

Graves Orbitopathy (GO) is an autoimmune inflammatory disorder causing visual morbidity, cosmetic morbidity and interference with quality of life. The disease has an inflammatory stage and a non-inflammatory, fibrotic stage.

Treatment of inflammatory stage moderate-severe GO includes steroids, as recommended by the EUGOGO consortium. However, the length of treatment needed and the risk of steroid side-effects may lead to multiple undesired treatment induced morbidity.

Antibiotics of the macrolide group posses known immune-modulatory effects that are separate from their antibacterial mode of action. This mode of action has lead to the routine use of macrolide antibiotics for delaying graft rejection following lung transplants.

We propose to test the effect of this class of antibiotics for non-sight threatening, moderate-severe, inflammatory GO.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of Graves Orbitopathy
  • Clinical activity score higher than 2
  • Must be able to swallow tablets

Exclusion Criteria:

  • sight-threatening Graves Orbitopathy
  • Diplopia in primary gaze
  • Macrolide allergy or intolerance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01379196

Sponsors and Collaborators
Rabin Medical Center
Principal Investigator: Hadas Kalish, MD Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva 49100 Israel
  More Information

Responsible Party: kalish hadas, Chief, Neuro-Ophthalmology Unit, Rabin Medical Center Identifier: NCT01379196     History of Changes
Other Study ID Numbers: 0427-10-RMC
Study First Received: May 11, 2011
Last Updated: April 25, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by kalish hadas, Rabin Medical Center:
Graves Orbitopathy
Macrolide antibiotics
Clinical Activity Score

Additional relevant MeSH terms:
Eye Diseases
Graves Ophthalmopathy
Eye Diseases, Hereditary
Graves Disease
Orbital Diseases
Thyroid Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 18, 2017